)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Monopar Therapeutics
Monopar Therapeutics (MNPR) investor relations material
Monopar Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary27 Mar, 2026
Executive summary
Achieved significant progress in 2025, including multiple ALXN1840 data presentations, a key publication, and leadership team expansion in preparation for a potential ALXN1840 launch.
Strengthened balance sheet and advanced toward a planned NDA submission for ALXN1840 in Wilson disease.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $140.4 million as of December 31, 2025.
Net loss for Q4 2025 was $5.2 million ($0.61/share), down from $10.9 million ($2.23/share) in Q4 2024.
Net loss for full-year 2025 was $13.7 million ($1.85/share), compared to $15.6 million ($4.11/share) in 2024.
R&D expenses for Q4 2025 were $3.9 million, down from $9.9 million in Q4 2024, mainly due to absence of one-time licensing costs.
G&A expenses for Q4 2025 rose to $2.2 million from $1.2 million in Q4 2024, driven by higher personnel and legal costs.
Outlook and guidance
Plans to submit NDA for ALXN1840 in Wilson disease in mid-2026 following recent FDA interactions.
Current funds expected to support operations through at least December 31, 2027, covering regulatory, commercial, and R&D activities.
Detail the mid-2026 NDA submission strategy
Discuss the US Phase 1 trial for MNPR-101-Lu
Explain the shift in R&D spending priorities
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Monopar Therapeutics
- ALXN1840 shows long-term efficacy in Wilson disease; MNPR-101 advances in oncology trials.MNPR
Investor presentation20 Mar 2026 - Biopharma seeks to raise up to $300M for rare disease and oncology pipeline via flexible shelf offering.MNPRRegistration Filing16 Dec 2025
- Registering 705,015 shares for resale by a pharma partner after a licensing and equity deal.MNPRRegistration Filing16 Dec 2025
- Biotech registers 882,761 shares for resale after $21M private placement to fund drug development.MNPRRegistration Filing16 Dec 2025
- Key votes include director elections, auditor ratification, a reverse split, and stock plan amendment.MNPRProxy Filing2 Dec 2025
- Key votes include director elections, auditor ratification, reverse split, and stock plan amendment.MNPRProxy Filing2 Dec 2025
- Annual meeting to vote on directors, executive pay, auditor, and board governance.MNPRProxy Filing2 Dec 2025
- Annual meeting to elect directors, approve pay, and ratify auditor, with board support.MNPRProxy Filing2 Dec 2025
- $143.7M cash post-raise supports late-stage ALXN1840 and radiopharma pipeline through 2027.MNPRQ3 202513 Nov 2025
Next Monopar Therapeutics earnings date
Q1 20268 May, 2026
Monopar Therapeutics
Next Monopar Therapeutics earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage